These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 12057076)
41. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K; Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107 [TBL] [Abstract][Full Text] [Related]
42. [A case of docetaxel-resistant lung cancer effectively treated with chemotherapy of gemcitabine and vinorelbine]. Daido K; Arita K; Ohashi N; Nakamura K Gan To Kagaku Ryoho; 2000 Oct; 27(11):1747-50. PubMed ID: 11057328 [TBL] [Abstract][Full Text] [Related]
44. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Simon GR; Bunn PA Cancer Invest; 2003; 21(1):87-104. PubMed ID: 12643013 [TBL] [Abstract][Full Text] [Related]
45. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Frasci G; Comella P; D'Aiuto G; Thomas R; Capasso I; Elmo M; Botti G; Cortino GR; Lapenta L; De Rosa V; Vallone P; Petrillo A; Comella G Ann Oncol; 2000 Mar; 11(3):367-71. PubMed ID: 10811508 [TBL] [Abstract][Full Text] [Related]
46. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents. Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816 [TBL] [Abstract][Full Text] [Related]
47. Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum. Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W; Onkologie; 2004 Feb; 27(1):58-64. PubMed ID: 15007250 [TBL] [Abstract][Full Text] [Related]
48. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial. Tas F; Demir C; Camlica H; Ustuner Z; Topuz E Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950 [TBL] [Abstract][Full Text] [Related]
51. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Copeland LJ; Bookman M; Trimble E; Gynecol Oncol; 2003 Aug; 90(2 Pt 2):S1-7. PubMed ID: 12927999 [TBL] [Abstract][Full Text] [Related]
52. [Two cases of complete response to combination chemotherapy of gemcitabine and docetaxel for recurrent ovarian cancer]. Ito K; Adachi S; Iijima T; Nakatsuji Y; Kimura T; Nobunaga T Gan To Kagaku Ryoho; 2003 Jan; 30(1):141-4. PubMed ID: 12557720 [TBL] [Abstract][Full Text] [Related]
53. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program. Ornstein DL; Nervi AM; Rigas JR Ann Oncol; 1999; 10 Suppl 5():S35-40. PubMed ID: 10582137 [TBL] [Abstract][Full Text] [Related]
54. Do newer chemotherapeutic agents improve survival in non-small cell lung cancer? Rigas JR Semin Oncol; 1998 Jun; 25(3 Suppl 8):5-9. PubMed ID: 9704669 [TBL] [Abstract][Full Text] [Related]
56. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Sehouli J; Stengel D; Oskay-Oezcelik G; Zeimet AG; Sommer H; Klare P; Stauch M; Paulenz A; Camara O; Keil E; Lichtenegger W J Clin Oncol; 2008 Jul; 26(19):3176-82. PubMed ID: 18591555 [TBL] [Abstract][Full Text] [Related]
57. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Griffiths RW; Zee YK; Evans S; Mitchell CL; Kumaran GC; Welch RS; Jayson GC; Clamp AR; Hasan J Int J Gynecol Cancer; 2011 Jan; 21(1):58-65. PubMed ID: 21178570 [TBL] [Abstract][Full Text] [Related]
58. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors. Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005 [TBL] [Abstract][Full Text] [Related]
59. Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience. O'Shaughnessy J Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):15-21. PubMed ID: 14768400 [TBL] [Abstract][Full Text] [Related]